Variations in cancer care causing avoidable deaths
It said this is causing avoidable deaths.
It said that new data identifies major variation in access to life-saving chemotherapy and radiotherapy treatment and delays for patients who have been referred for urgent breast and prostate tests.
Dr Michael McCarthy, President of the Irish Society of Medical Oncology, and consultant oncologist at University Hospital Galway, said that working in the West of Ireland, he sees the human cost of the postcode lottery in Irish cancer care every day.
He said that once chemotherapy is prescribed, the National Cancer Strategy states that it should start within 15 working days.
Dr McCarthy said the reality in Galway is that patients are now typically waiting seven to eight weeks for their first session.
He added that with every week that passes, the risk increases that their cancer will grow, or worse it will spread to other parts of their body.
He said that the system does not have enough staff, space or equipment to cope and patients are paying the price.
Investment impacting cancer care and outcomes
The HSE said that investment is having a real and measurable impact on access to cancer care and outcomes.
It added that the service is committed to ensuring all patients get timely and equitable access to cancer treatment.
ICS chief executive, Averil Power said that a person's chances of surviving cancer are up to four times higher when treated at Stage 1 than at Stage 4.
The ICS said that some radiotherapy equipment with a useful life of 10 years is now 17 years old and subject to significantly more downtime for maintenance and repairs as a result.
It said there are no PET scanners in the public cancer centres in Galway, Waterford or Limerick.
The Society said there are big variations in waiting times for patients to be seen at rapid access clinics for urgent symptomatic breast disease, urgent lung and prostate cases.
Nationally from March 2024-February 2025, it said that only just over 73% of patients got their first appointment within the recommended time frame.
It added that the HSE Key Performance Indicators (KPIs) only record the patient's waiting for a first appointment at the Rapid Access Clinics, not how long they have to wait for diagnostic tests to determine if they have cancer.
The Society said that increasingly, tests that would have been performed on the first appointment date are not now taking place until weeks or months later.
Cancer survival rates improving - HSE
In response to the ICS statement, the HSE said that cancer survival is improving and that more people are living after cancer than ever before.
It added that today over 220,000 people here are living with or after cancer, which is a 50% increase compared with a decade ago.
The HSE said that during the lifetime of the current National Cancer Strategy 2017-2026, the National Cancer Control Programme has allocated around €90m for the development of services, including €20m for new services this year and next year.
The HSE said this has supported the created the creation of 800 wholetime posts across the public cancer services, including 12 consultants, 300 nurses and 300 health and social care professionals.
Around 40,000 cancers or related tumours are diagnosed here each year.
The overall burden of cancer in Ireland is increasing, particularly due to population growth and ageing.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Journal
2 hours ago
- The Journal
The millionaire millennial seeking the presidency: How did Gareth Sheridan get so rich?
BUSINESSMAN GARETH SHERIDAN is seeking to become the youngest-ever Irish presidential candidate during this year's election, and claims to have secured support to make that possible. Much of the Irish public were introduced to 35-year-old Sheridan for the first time this week as a millionaire, pharmaceutical tycoon who recently returned to Ireland having spent the last seven years building up his company in the US. But how, exactly, did he earn his millions? And what does his company do? Acquisitions and mergers Nurtiband, a US-based healthcare-led company valued at approximately $80m, was started by Sheridan in 2012, during his final year at DIT in Dublin, where he was studying businesses and management. Taking inspiration from a transdermal patch his father had for a heart condition, Sheridan wrote his undergraduate thesis on providing properly-dosed medicine to patients through more accessible means, like patches, which are less likely to abuse. Early social media posts from Sheridan show that the company began by selling supplements, such as energy and metabolism-boosting patches, but the Dubliner wanted to branch out into the opioid market. Former Áras contender Seán Gallagher was later enlisted as the company's President (he has since left and has no current relationship with Sheridan) as the CEO worked towards getting the company listed on the Nasdaq stock exchange. Nutriband's strategy focused on carrying out a number of mergers and acquisitions, purchasing companies through its own stock options as a private company, over the last ten years, Sheridan explained on The Entrepreneur Experiment podcast in April. Sheridan focused on merging with firms with existing specialities in pharmaceuticals and biotechnology. It listed on the New York-based stock exchanged in October 2023, generating over $6m on its first day. Nutriband has now focused wholly on opioids through transdermal patches – similar to products used for nicotine-replacement therapy. Opioids, a type of pain-relief medication, have proven to be addictive among some patients. While they are an effective method to treat chronic pain, doctors – particularly in the US – have been reluctant to prescribe the medicines. Image posted by Sheridan in 2023 after his company was listed on the Nasdaq stock exchange in New York. Gareth Sheridan Gareth Sheridan As a result, more people have sought to purchase opioids illegally, and the black market drugs trade responded by introducing potent or synthetic alternatives over the last decade. The most-famous of these in the US is fentanyl, currently. Sheridan said that the most-important of Nutriband's acquisitions was the purchase of 4P Therapeutics in 2018, a company from two pharma veterans who created AVERSA technology , which prevents the misuse of opioids. It is today his lead product. During one acquisition, Nutriband pulled out of purchasing the manufacturer of transdermal patches . It was subsequently reported that a lawyer representing the firm did not disclose their ownership position in both companies. Asked about this on RTÉ Radio One yesterday, Sheridan explained that it was the only time that his firm had faced any trouble with US authorities and that, for Nutriband, it was seen as a minor issue and required the firm to correct submitted paperwork. Advertisement Unique selling point Sheridan has said he wants Nutriband to benefit those who are ill, developing patches that provide patients with a safe dose of medicines that are commonly abused – primarily opioids – targeting those who are in need of the controversial medicines. If abused, the drugs can cause long-term health complications, impact organ health and – in the case of synthetic and potent alternatives especially – minor doses can result in death. We're up and running! Excited to have announced my intention to seek a nomination for the upcoming Presidential election. I look forward to setting out my values and vision for the Presidency over the coming days and continuing to engage with Councillors across the country. — Gareth Sheridan (@GPSheridan1) August 11, 2025 Sheridan's business case is that there are still many people, in the US particularly, who need these pain medicines for proper health-related reasons. He believes the managed doses from his firm's patches is a unique selling point and a prevention of abuse and addiction. He said that there's been an increase of American patients being told to use over-the-counter pain medication for illnesses, and claims his patches could be a safer and more appropriate option. Pharmaceutical patches Sheridan in April said acquisitions and mergers were 'the strategy' for the company. Some of the previous owners from the purchased companies went on to join Sheridan and held positions at Nutriband for a short time. He explained, due to his own lack of expertise in pharmacology, he needed those who could help actually develop his ideas. He added: 'It also kept us away from expensive money. I am able to retain today a good proportion of the company because we didn't do angel [investor] rounds, seed rounds. We didn't do the traditional route.' News reports of the company's activities recently have focused on its newest patch, which would deliver a proper prescribed dose of fentanyl . The firm is still in ongoing discussions with the US's drugs regulator, the Food and Drug Administration. In preparation for its approval, it has offered shareholders particular stock options to raise funds. Success? Nutriband is yet to generate any revenue. In its most-recent public quarterly report, at the end of October last year, it recorded a net-loss of $1.3m. Speaking to The Entrepreneur Experiment in April, Sheridan said: 'In most public companies it's either one person makes a million dollars or, years later, dozens of people make multiple millions of dollars. So there's patience and trust involved.' The Áras hopeful, who has stepped back as CEO from Nutriband to pursuit the election later this year, said he is certain the company will be worth a billion dollars in the future. Sheridan said the firm has been careful not to waste any funding too: 'We've been very careful not to raise money that we don't need – money that is sitting in a bank account at the expense of shareholders [...] It's just little things like that.' He told RTÉ Radio One yesterday that he believes Nutriband will still achieve that goal, with or without him. He said that he intends to have a stake in the firm, should he be placed on the ballot and elected President. Sheridan said he is seeking to be nominated as a candidate to represent the interests of young people who feel that they must emigrate for work and other opportunities due to the housing situation here. He is due to announced his platform's values later this week. Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal
Irish Independent
5 hours ago
- Irish Independent
State ‘completely failed' boy who died after waiting for scoliosis surgery
'What we went through was horrific' – families angry after Swiss clinic helped Irish woman to die in secret despite its promises
Irish Independent
5 hours ago
- Irish Independent
Consultant backs initiative between HSE and Parkrun on participation for those living with Dementia
Parkrun in Sligo and Leitrim are welcoming people living with Dementia, their families and carers to take part in their local runs. The HSE and Parkrun Ireland have recently launched a Dementia Friendly Parkrun Manual. The manual reflects Parkrun's ongoing commitment to removing barriers to participation and promoting physical, social, and mental wellbeing for all. Speaking about the initiative, Professor Paula Hickey, Consultant Geriatrician Sligo University Hospital said: 'I am delighted to support the Dementia Friendly Parkrun Manual. 'This is a valuable initiative to create a welcoming space for people living with dementia, their family, friends and carers. 'Maintaining an active life with social engagement is such a fundamental part of living well with dementia, this practical action can make a big difference and helps promote inclusive friendly communities.' Parkrun Ireland have been working with HSE Health and Wellbeing for many years supporting and driving engagement in physical activity. The new initiative is designed to make parkrun's across the country more welcoming and inclusive for people living with dementia. People with dementia or family members who are caring for a person with dementia may consider taking part or volunteering in their local parkrun as a good physical or social activity. Doing things with others and taking part in worthwhile activities can improve the quality of life of people living with dementia. It may also slow the development of dementia. Parkrun is a safe and friendly way to get regular activity. Whether walking, jogging or running - anyone can join in. Parkrun is a free weekly run, jog or walk for all, taking place on Saturday mornings at 9.30am. Its locations in Sligo and Leitrim are: Sligo Parkrun - Doorly Park, Cleveragh, Sligo Tubbercurry Trail Parkrun- Tubbercurry Trail, Ballina Rd, Rathscanlon, Tubbercurry, Co. Sligo Glenfarne Wood Parkrun- Glenfarne Wood, Moneyduff, Co. Leitrim. Ballinamore Greenway Parkrun- Ballinamore Greenway, Ballinamore, Co Leitrim. The manual is available to order free of charge from (direct link:
